ID   CCNT1_MOUSE             Reviewed;         724 AA.
AC   Q9QWV9; Q3V0G4; Q9Z0U7;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 3.
DT   18-JUN-2025, entry version 188.
DE   RecName: Full=Cyclin-T1;
DE            Short=CycT1;
DE            Short=Cyclin-T;
GN   Name=Ccnt1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/cJ;
RX   PubMed=9843510; DOI=10.1093/emboj/17.23.7056;
RA   Bieniasz P.D., Grdina T.A., Bogerd H.P., Cullen B.R.;
RT   "Recruitment of a protein complex containing Tat and cyclin T1 to TAR
RT   governs the species specificity of HIV-1 Tat.";
RL   EMBO J. 17:7056-7065(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF TYR-261.
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=9832504; DOI=10.1101/gad.12.22.3512;
RA   Garber M.E., Wei P., KewalRamani V.N., Mayall T.P., Herrmann C.H.,
RA   Rice A.P., Littman D.R., Jones K.A.;
RT   "The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a
RT   critical cysteine residue that is not conserved in the murine CycT1
RT   protein.";
RL   Genes Dev. 12:3512-3527(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF ARG-256; TYR-261; GLN-262;
RP   MET-265 AND ASN-277.
RC   TISSUE=Spleen;
RX   PubMed=10329126; DOI=10.1006/jmbi.1999.2664;
RA   Kwak Y.T., Ivanov D., Guo J., Nee E., Gaynor R.B.;
RT   "Role of the human and murine cyclin T proteins in regulating HIV-1 Tat-
RT   activation.";
RL   J. Mol. Biol. 288:57-69(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTAGENESIS OF ARG-256; TYR-261; GLN-262;
RP   MET-265 AND ASN-277.
RC   TISSUE=Fibroblast;
RX   PubMed=9990016; DOI=10.1073/pnas.96.4.1285;
RA   Fujinaga K., Taube R., Wimmer J., Cujec T.P., Peterlin B.M.;
RT   "Interactions between human cyclin T, Tat, and the transactivation response
RT   element (TAR) are disrupted by a cysteine to tyrosine substitution found in
RT   mouse cyclin T.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1285-1290(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Testis;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH TBX21 AND CDK9.
RX   PubMed=27292648; DOI=10.1016/j.celrep.2016.05.054;
RA   Hertweck A., Evans C.M., Eskandarpour M., Lau J.C., Oleinika K.,
RA   Jackson I., Kelly A., Ambrose J., Adamson P., Cousins D.J., Lavender P.,
RA   Calder V.L., Lord G.M., Jenner R.G.;
RT   "T-bet activates Th1 genes through mediator and the super elongation
RT   complex.";
RL   Cell Rep. 15:2756-2770(2016).
CC   -!- FUNCTION: Regulatory subunit of the cyclin-dependent kinase pair
CC       (CDK9/cyclin-T1) complex, also called positive transcription elongation
CC       factor B (P-TEFb), which facilitates the transition from abortive to
CC       productive elongation by phosphorylating the CTD (C-terminal domain) of
CC       the large subunit of RNA polymerase II (RNA Pol II). Required to
CC       activate the protein kinase activity of CDK9: acts by mediating
CC       formation of liquid-liquid phase separation (LLPS) that enhances
CC       binding of P-TEFb to the CTD of RNA Pol II.
CC       {ECO:0000250|UniProtKB:O60563}.
CC   -!- SUBUNIT: Cyclin-T1 is the predominant cyclin that associates with CDK9
CC       to form a heterodimer called P-TEFb (PubMed:27292648). P-TEFb forms a
CC       complex with AFF4/AF5Q31 (By similarity). Component of a complex which
CC       is at least composed of HTATSF1/Tat-SF1, P-TEFb complex, RNA pol II,
CC       SUPT5H, and NCL/nucleolin (By similarity). Component of the 7SK snRNP
CC       complex at least composed of P-TEFb (composed of CDK9 and CCNT1/cyclin-
CC       T1), HEXIM1, HEXIM2, BCDIN3, SART3 proteins and 7SK and U6 snRNAs (By
CC       similarity). Interacts (via central region) with ZMYND8 (via N-
CC       terminus); the interaction is direct and the association appears to
CC       occur between homodimeric ZMYND8 and the activated form of the P-TEFb
CC       complex (By similarity). Interacts with BRD4, targets chromatin binding
CC       (By similarity). Interacts with JMJD6 (By similarity). Interacts with
CC       MDFIC (By similarity). Interacts with HSF1. Interacts with HTATSF1 (By
CC       similarity). Interacts with TBX21 (PubMed:27292648).
CC       {ECO:0000250|UniProtKB:O60563, ECO:0000269|PubMed:27292648}.
CC   -!- INTERACTION:
CC       Q9QWV9; Q91Y44: Brdt; NbExp=2; IntAct=EBI-2655009, EBI-6260929;
CC       Q9QWV9; P28574: Max; NbExp=2; IntAct=EBI-2655009, EBI-1183003;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O60563}.
CC   -!- DOMAIN: The histidine-rich domain (HRD) region is intrinsically
CC       disordered and promotes the formation of phase-separated liquid
CC       droplets that enhance binding of the P-TEFb complex to the CTD (C-
CC       terminal domain) of the large subunit of RNA polymerase II (RNA Pol
CC       II). {ECO:0000250|UniProtKB:O60563}.
CC   -!- PTM: ADP-ribosylation on serine residues by PARP1 in response to DNA
CC       damage disrupts the phase separation activity of CCNT1, thereby
CC       preventing activation of CDK9. {ECO:0000250|UniProtKB:O60563}.
CC   -!- SIMILARITY: Belongs to the cyclin family. Cyclin C subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF095640; AAD13656.1; -; mRNA.
DR   EMBL; AF109179; AAD19654.1; -; mRNA.
DR   EMBL; AF087662; AAD17798.1; -; mRNA.
DR   EMBL; AF113951; AAD17205.1; -; mRNA.
DR   EMBL; AK133168; BAE21540.1; -; mRNA.
DR   EMBL; AC138221; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC131685; AAI31686.1; -; mRNA.
DR   CCDS; CCDS27797.1; -.
DR   RefSeq; NP_033963.1; NM_009833.2.
DR   AlphaFoldDB; Q9QWV9; -.
DR   SMR; Q9QWV9; -.
DR   BioGRID; 198559; 5.
DR   ComplexPortal; CPX-230; Positive transcription elongation factor B, CDK9-cyclinT1 complex.
DR   CORUM; Q9QWV9; -.
DR   FunCoup; Q9QWV9; 3903.
DR   IntAct; Q9QWV9; 6.
DR   MINT; Q9QWV9; -.
DR   STRING; 10090.ENSMUSP00000126874; -.
DR   GlyGen; Q9QWV9; 1 site.
DR   iPTMnet; Q9QWV9; -.
DR   PhosphoSitePlus; Q9QWV9; -.
DR   PaxDb; 10090-ENSMUSP00000126874; -.
DR   PeptideAtlas; Q9QWV9; -.
DR   ProteomicsDB; 281342; -.
DR   Pumba; Q9QWV9; -.
DR   Antibodypedia; 1442; 292 antibodies from 38 providers.
DR   DNASU; 12455; -.
DR   Ensembl; ENSMUST00000012104.7; ENSMUSP00000012104.7; ENSMUSG00000011960.13.
DR   Ensembl; ENSMUST00000169707.8; ENSMUSP00000126874.2; ENSMUSG00000011960.13.
DR   GeneID; 12455; -.
DR   KEGG; mmu:12455; -.
DR   UCSC; uc007xmv.1; mouse.
DR   AGR; MGI:1328363; -.
DR   CTD; 904; -.
DR   MGI; MGI:1328363; Ccnt1.
DR   VEuPathDB; HostDB:ENSMUSG00000011960; -.
DR   eggNOG; KOG0834; Eukaryota.
DR   GeneTree; ENSGT00940000159544; -.
DR   HOGENOM; CLU_012994_1_0_1; -.
DR   InParanoid; Q9QWV9; -.
DR   OMA; TWSGKGQ; -.
DR   OrthoDB; 25002at2759; -.
DR   PhylomeDB; Q9QWV9; -.
DR   Reactome; R-MMU-112382; Formation of RNA Pol II elongation complex.
DR   Reactome; R-MMU-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-MMU-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-MMU-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-MMU-6807505; RNA polymerase II transcribes snRNA genes.
DR   Reactome; R-MMU-75955; RNA Polymerase II Transcription Elongation.
DR   Reactome; R-MMU-9018519; Estrogen-dependent gene expression.
DR   BioGRID-ORCS; 12455; 17 hits in 80 CRISPR screens.
DR   ChiTaRS; Ccnt1; mouse.
DR   PRO; PR:Q9QWV9; -.
DR   Proteomes; UP000000589; Chromosome 15.
DR   RNAct; Q9QWV9; protein.
DR   Bgee; ENSMUSG00000011960; Expressed in rostral migratory stream and 253 other cell types or tissues.
DR   ExpressionAtlas; Q9QWV9; baseline and differential.
DR   GO; GO:0008024; C:cyclin/CDK positive transcription elongation factor complex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0070691; C:P-TEFb complex; ISS:UniProtKB.
DR   GO; GO:0097322; F:7SK snRNA binding; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0061575; F:cyclin-dependent protein serine/threonine kinase activator activity; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; ISO:MGI.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IEA:Ensembl.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IDA:MGI.
DR   GO; GO:0070063; F:RNA polymerase binding; IEA:Ensembl.
DR   GO; GO:0017069; F:snRNA binding; IDA:MGI.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; IDA:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0043923; P:positive regulation by host of viral transcription; IEA:Ensembl.
DR   GO; GO:0032968; P:positive regulation of transcription elongation by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   CDD; cd20597; CYCLIN_CCNT1_rpt2; 1.
DR   FunFam; 1.10.472.10:FF:000004; Cyclin T2; 1.
DR   FunFam; 1.10.472.10:FF:000009; cyclin-T2 isoform X1; 1.
DR   Gene3D; 1.10.472.10; Cyclin-like; 2.
DR   InterPro; IPR013763; Cyclin-like_dom.
DR   InterPro; IPR036915; Cyclin-like_sf.
DR   InterPro; IPR043198; Cyclin/Ssn8.
DR   InterPro; IPR047320; CYCLIN_CCNT1_rpt2.
DR   InterPro; IPR006671; Cyclin_N.
DR   PANTHER; PTHR10026; CYCLIN; 1.
DR   Pfam; PF00134; Cyclin_N; 1.
DR   Pfam; PF21797; CycT2-like_C; 1.
DR   SMART; SM00385; CYCLIN; 1.
DR   SUPFAM; SSF47954; Cyclin-like; 2.
DR   TreeFam; TF101014; -.
PE   1: Evidence at protein level;
KW   Acetylation; ADP-ribosylation; Cell cycle; Cell division; Coiled coil;
KW   Cyclin; Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..724
FT                   /note="Cyclin-T1"
FT                   /id="PRO_0000080493"
FT   REGION          479..549
FT                   /note="Histidine-rich domain (HRD)"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   REGION          483..586
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          691..724
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          384..425
FT                   /evidence="ECO:0000255"
FT   MOTIF           253..270
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        483..507
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        508..529
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        559..569
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        708..724
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         117
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         388
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         390
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         416
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         473
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         474
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         484
FT                   /note="N6-(ADP-ribosyl)lysine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         486
FT                   /note="ADP-ribosylhistidine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         494
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         529
FT                   /note="ADP-ribosylhistidine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         548
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         551
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         555
FT                   /note="ADP-ribosylhistidine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MOD_RES         562
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   CROSSLNK        342
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   CROSSLNK        415
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   CROSSLNK        480
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O60563"
FT   MUTAGEN         256
FT                   /note="R->W: No effect."
FT                   /evidence="ECO:0000269|PubMed:10329126"
FT   MUTAGEN         261
FT                   /note="Y->C: Binding to HIV-1 Tat similar to human CCNT1."
FT                   /evidence="ECO:0000269|PubMed:10329126,
FT                   ECO:0000269|PubMed:9832504"
FT   MUTAGEN         262
FT                   /note="Q->E: No effect."
FT                   /evidence="ECO:0000269|PubMed:10329126"
FT   MUTAGEN         265
FT                   /note="M->K: No effect."
FT                   /evidence="ECO:0000269|PubMed:10329126"
FT   MUTAGEN         277
FT                   /note="N->K: No effect."
FT                   /evidence="ECO:0000269|PubMed:10329126"
FT   CONFLICT        48
FT                   /note="M -> V (in Ref. 3; AAD19654)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        567
FT                   /note="S -> F (in Ref. 4; AAD17205)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   724 AA;  80598 MW;  6D090F5CA7C3A79C CRC64;
     MEGERKNNNK RWYFTREQLE NSPSRRFGVD SDKELSYRQQ AANLLQDMGQ RLNVSQLTIN
     TAIVYMHRFY MIQSFTQFHR YSMAPAALFL AAKVEEQPKK LEHVIKVAHT CLHPQESLPD
     TRSEAYLQQV QDLVILESII LQTLGFELTI DHPHTHVVKC TQLVRASKDL AQTSYFMATN
     SLHLTTFSLQ YTPPVVACVC IHLACKWSNW EIPVSTDGKH WWEYVDATVT LELLDELTHE
     FLQILEKTPS RLKRIRNWRA YQAAMKTKPD DRGADENTSE QTILNMISQT SSDTTIAGLM
     SMSTASTSAV PSLPSSEESS SSLTSVDMLQ GERWLSSQPP FKLEAAQGHR TSESLALIGV
     DHSLQQDGSS AFGSQKQASK SVPSAKVSLK EYRAKHAEEL AAQKRQLENM EANVKSQYAY
     AAQNLLSHDS HSSVILKMPI ESSENPERPF LDKADKSALK MRLPVASGDK AVSSKPEEIK
     MRIKVHSAGD KHNSIEDSVT KSREHKEKQR THPSNHHHHH NHHSHRHSHL QLPAGPVSKR
     PSDPKHSSQT STLAHKTYSL SSTLSSSSST RKRGPPEETG AAVFDHPAKI AKSTKSSLNF
     PFPPLPTMTQ LPGHSSDTSG LPFSQPSCKT RVPHMKLDKG PPGANGHNAT QSIDYQDTVN
     MLHSLLSAQG VQPTQAPAFE FVHSYGEYMN PRAGAISSRS GTTDKPRPPP LPSEPPPPLP
     PLPK
//
